(19)
(11) EP 0 705 344 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 2 (W2 B1)

(48) Corrigendum issued on:
10.05.2006 Bulletin 2006/19

(45) Mention of the grant of the patent:
14.09.2005 Bulletin 2005/37

(21) Application number: 94920351.7

(22) Date of filing: 24.06.1994
(51) International Patent Classification (IPC): 
C12N 15/861(2000.01)
 C12N 15/00(1980.01)
(86) International application number:
PCT/CA1994/000364
(87) International publication number:
WO 1995/000655 (05.01.1995 Gazette 1995/02)

(54)

ADENOVIRUS VECTORS FOR GENE THERAPY

ADENOVIRUS VEKTOREN FÜR GENTHERAPIE

VECTEURS A BASE D'ADENOVIRUS DESTINES A LA THERAPIE GENIQUE

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

(30) Priority: 24.06.1993 US 80727
31.05.1994 US 250885

(43) Date of publication of application:
10.04.1996 Bulletin 1996/15

(73) Proprietor: ADVEC INC.
Ancaster ON L9G 28S (CA)

(72) Inventors:
  • Graham, Frank L
    Ontario L8P 2V4 (CA)
  • Bett, Andrew
    Ontario L8S 4H6 (CA)
  • Prevek, Ludvik
    Ontario L7T 1M9 (CA)
  • Haddara, Wael
    Ontario L8S 1A1 (CA)

(74) Representative: Germinario, Claudio et al
Società Italiana Brevetti S.p.A. Piazza di Pietra 39
00186 Roma
00186 Roma (IT)


(56) References cited: : 
WO-A-93/06223
WO-A-93/19191
WO-A-94/12649
 WO-A-93/19092
WO-A-94/08026
   
  • PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol.89, no.7, 1 April 1992, WASHINGTON US pages 2581 - 2584 QUANTIN ET AL. 'Adenovirus as an expressionvector in muscle cells in vivo'
  • CELL., vol.68, no.1, 10 January 1992, CAMBRIDGE, NA US pages 143 - 155 ROSENFELD ET AL. 'In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium'
  • JOURNAL OF VIROLOGY, vol. 61, no. 8, August 1987 (1987-08), pages 2555-2558,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).